Cidara gets $30m up front for US rights to the weekly echinocandin candidate for candidemia and invasive candidiasis. Takeda walks away from oncolytic virus candidate licensed from Turnstone.

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Executives On The Move will be running to a monthly schedule from now, with this edition covering medtech's executive changes for April.

Also, Cytovia will go public via SPAC merger, Nkarta capitalized on its positive early NK cell therapy data with a $230m offering, and venture capital mega-rounds include $220m for Reify, $110m for Satellite Bio and $100m for OMass Therapeutics.